Weight-Loss Drugs Like Ozempic Would Be Covered By Medicare And Medicaid Under Biden Plan
Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden on Tuesday, increasing access to the widely popular medications to millions of adults with obesity in the U.S., though the plan would likely face opposition under President-elect Donald Trump's second administration.
Novo Nordisk Stock Surges as Biden Advocates Medicare Coverage for Weight-Loss Drugs
Shares of Novo Nordisk jumped 1.3% after President Biden proposed expanding Medicare and Medicaid coverage for weight-loss drugs. Currently covering certain conditions, the changes could become effective in 2026,
Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...
The Novo Nordisk Foundation’s assets have swelled with the success of diabetes and obesity treatments Ozempic and ...
Joe Biden's term as President of the United States is set to end on January 20, 2025. In his rest of his time, his ...
Bloomberg on MSN1d
Novo Nordisk Is Scaling Back Its Hiring Spree in Denmark(Bloomberg) -- Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s ...
Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Jo Biden proposed expanding ...
Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
President-elect Donald J. Trump is set to nominate Robert F. Kennedy Jr. to lead the Health and Human Services Department, ...
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback